Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Atopic Eczema (US)

Articles with lock require a subscription to GLG News | Request a free trial
Sunil DhawanNovember 12, 2007
Stifel and Allergan collaboration very positive
Analysis of: Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recently announced collaboartion between Stiefel and Allergan in regards to Tazorac is very positive. Stiefel needs this molecule to put into different dosage forms, and in combination with its existing products espoecially Duac, etc. Their current acne product line is strong, but this will solodify...
November 8, 2007
me too drug!
Analysis of: A.T.S. Pharmaceuticals, A Division Of Auriga Laboratories, Launches Coraz™ Lotion For The Treatment Of Seborrheic Dermatitis | www.medicalnewstoday.com
Author: GLG Expert Contributor
Why bother with this branded 2% hydrocortisone lotion?  Likely third tier, and nothing special other than the gimicky wash that goes along with it.  The lotion is a very weak %of steroid- so probably minimally useful. ? pediatric indication, would possibly have some hope for the product.
Sunil DhawanOctober 8, 2007
Abbotts ABT-874 shows good results in Psoriasis
Analysis of: Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Abbotts ABT-874 monoclonal antibody for psoriasis shows impressive results in the phase 2 trial. The results were up to 90% of patients achieving at least 75% reduction in their psoriasis. These results are as good or better than those with Remicade the most effective biologic for psoriasis currently....
Sunil DhawanSeptember 28, 2007
Relieva results in recent clinical trial for eczema
Analysis of: Relieva Exceeds Expectations In Recent Clinical Trial For Eczema (Atopic Dermatitis) | www.medicalnewstoday.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent results for a trial of Relieva in atopic dermatitis or eczema, a cream containing a homeopathic compound, were positive by a report from the company. The study sample was small, and the trial was open label. Generally these trials have a larger number of patients, and are blinded. Also it...
September 24, 2007
This treatment is unsafe and regulation is going to make it obsolete for a time
Analysis of: Feel Pudgy? There’s a Shot for That | www.nytimes.com
Author: GLG Expert Contributor
This treatment is run illegally, in violation of FDA laws Additionally, it is outlawed in Europe, Canada and Brazil, among other places Lastly, it isn't all that effective, from what I hear, and very painful.  In summary, better options will become available.
Sunil DhawanSeptember 10, 2007
FDA issues warning to Melanocorp
Analysis of: FDA Issues Warning Letter To Melanocorp, Inc. For Illegal Sale Of Melanotan II -Agency Warns Consumers About Using And Purchasing Unapproved Product | www.medicalnewstoday.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
 The FDA warning to Melanocorp regarding their product Melanotan was justified. These warnings are far too few and infrequent, and numerous companies make claims without studies or substantiation. The agency is overwhelmed with NDA's, and has difficulty handling the work that currently exists....
August 17, 2007
A Novel Approach to Infection - No More Staph Meetings!
Analysis of: NUCRYST Pharmaceuticals Receives FDA Clearance Of Antimicrobial Barrier Topical Cream | www.medicalnewstoday.com
Author: GLG Expert Contributor
+ Novel antimicrobial barrier will have broad implications for both prophylaxis post-operatively as well as for dermatologic conditions that are suceptible to superinfection (i.e. atopic dermatitis)
August 16, 2007
Lasers for Spider Vein (Phlebectasia) Treatment are Good Enough
Analysis of: Recurrence of Spider Angiomas After Laser Treatment | dermatology.jwatch.org
Author: GLG Expert Contributor
+ Recurrence rates for outdated lasers are a mute point. + The current generation of lasers for vascular lesions are standard of care and deliver as promised.
Sunil DhawanJuly 12, 2007
Vaniqa's effect on laser hair removal
Analysis of: Laser Hair Removal Enhanced With Eflornithine Cream | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
I do not believe that Vaniqa will have a negative effect on Laser hair removal as its efficacy is only temporary. In fact we use it as an adjunct for patients with resistant areas. Its use may actually enhance the use of Laser devices as they offer permanence. The products use may be increasing as more...
Sunil DhawanJune 18, 2007
Dermlex Launch
Analysis of: Advitech to finally launch Dermylex in US | www.nutraingredients-usa.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Advitech's launch of Dermylex will not have much of an impact on the psoriasis market. This is due to the fact that the product has minimal studies to back it up, and the company will rely on testimonials. This is not an effective way of marketing to physicians, and is difficult with patients....

Previous Page : 1 2 3 4 5 6 7 8 Next41 to 50 of 80

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203